Cited by 361Antifungal resistance and susceptibilityBacterial Identification and Susceptibility TestingFungal Infections and Studies

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Has antifungal susceptibility testing come of age

Rex, John H., Pfaller, Michael A.·2002·Clinical Infectious Diseases

DOI 10.1086/342384

Open this paper in CoChat — free account

Abstract

The in vitro susceptibility of an infecting organism to the antimicrobial agent selected for therapy is one of several factors that influence the likelihood that therapy for an infection will be successful. To appreciate the value of antifungal susceptibility testing, it is helpful to review the overall predictive utility of antibacterial susceptibility testing. After >30 years of study, in vitro susceptibility can be said to predict the response of bacterial infections with an accuracy that is well summarized as the "90-60 rule": infections due to susceptible isolates respond to therapy approximately 90% of the time, whereas infections due to resistant isolates respond approximately 60% of the time. On the basis of a growing body of knowledge, standardized susceptibility testing for selected organism-drug combinations (most notably, Candida species and the azole antifungal agents) has been shown to have similar predictive utility. Antifungal susceptibility testing is now increasingly and appropriately used as a routine adjunct to the treatment of fungal infections.

Integrity signals

Registry

Crossref · 10.1086/342384

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults
Weinstein, M. P., Towns, M., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Reller, L. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,225
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,143
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Anthrax
Dixon, T. C., Meselson, M. S., Guillemin, J. H., & Hanna, P. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411107 · Cited by 871
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citation
The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. II. Clinical Observations, with Special Reference to Factors Influencing Prognosis
Weinstein, M. P., Murphy, J. R., Reller, L. B., & Lichtenstein, K. A. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.1.54 · Cited by 471
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citation
In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens
Espinel-Ingroff, A. V. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.198-202.1998 · Cited by 357

Show all 64 references

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citation
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citation
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citation
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Self-citation
Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494
Self-citation
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Self-citation
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 452
When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing
Doern, C. D. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01121-14 · Cited by 434
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
Richter, S. S., Galask, R. P., Messer, S. A., Hollis, R. J., Diekema, D. J., & Pfaller, M. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2155-2162.2005 · Cited by 435
Self-citation
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Motsch, J., de Oliveira, C. M., Stus, V. P., Köksal, İ., Lyulko, O. O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 424
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Carmeli, Y., Armstrong, J. M., Laud, P. J., Newell, P., Stone, G. G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 424
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 409
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Hu, B., Dzierzanowska, D., Климко, Н. Н., Letscher‐Bru, V., Lisalová, M., Muehlethaler, K., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Self-citation
Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352
Self-citation
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Self-citation
The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 311
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 300
Self-citation
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F. G. M., Gould, I. M., Fu, W., Colombo, A. L., & Rodríguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 287
Self-citation
Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens
Marangon, F. B., Miller, D., Giaconi, J. A., & Alfonso, E. C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.078 · Cited by 264
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citation
Invasive candidiasis in the intensive care unit
Ostrosky-Zeichner, L., & Pappas, P. G. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201897.78123.44 · Cited by 247
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Self-citation
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A. A., Carvalho, A., Houbraken, J. A. M. P., Lombardi, L., Garcia‐Rubio, R., Jenks, J. D., Rivero-Menéndez, O., Aljohani, R., Jacobsen, I. D., Berman, J. G., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 262
Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing
Ersoy, S. C., Heithoff, D. M., Barnes, L., V, Tripp, G. K., House, J. K., Marth, J. D., Smith, J. W., & Mahan, M. J. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.026 · Cited by 213
Candida guilliermondii , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
Pfaller, M. A., Diekema, D. J., Méndez, M., Kibbler, C. C., Erzsebet, P., Chang, S., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 192
Self-citation
Therapeutic potential of antifungal plant and insect defensins
Thevissen, K., Kristensen, H., Thomma, B. P. H. J., Cammue, B. P. A., & François, I. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.016 · Cited by 179
Anti-Candida albicans natural products, sources of new antifungal drugs: A review
Zida, A., Bamba, S., Yacouba, A., Ouedraogo-Traoré, R., & Guiguemdé, R. T. (2016) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2016.10.002 · Cited by 182
Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
Clancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 175
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
Self-citation
Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis
Lalitha, P. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.6.789 · Cited by 173
Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods
Fothergill, A. W. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_2 · Cited by 172
The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata
Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia
Pai, M. P., Turpin, R. S., & Garey, K. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 160
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal
Loyse, A., Dromer, F., Day, J., Lortholary, O., & Harrison, T. S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt221 · Cited by 163
Development of a DNA Microarray for Detection and Identification of Fungal Pathogens Involved in Invasive Mycoses
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155
Current status of antifungal susceptibility testing methods
Arikan, S. (2007) · Medical Mycology · doi:10.1080/13693780701436794 · Cited by 152
Contemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147
Self-citation
Overview of Antifungal Agents
Thompson, G. R., Cadena, J., & Patterson, T. F. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.001 · Cited by 142
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 140
Correlation of In Vitro Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris
Khurana, A., Masih, A., Chowdhary, A., Sardana, K., Borker, S. A., Gupta, A., Gautam, R. K., Sharma, P. K., & Jain, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01038-18 · Cited by 134
The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests
Doern, G. V., & Brecher, S. M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00580-11 · Cited by 132
Recent experience with fungaemia: change in species distribution and azole resistance
Chakrabarti, A., Chatterjee, S. S., Rao, K. L. N., Zameer, M., Rudramurthy, S. M., Singhi, S. C., Singh, R., & Varma, S. C. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540902777105 · Cited by 133
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citation
Candidemia in a Tertiary Care Cancer Center
Antoniadou, A., Torres, H. A., Lewis, R. E., Thornby, J. A., Bodey, G. P., Tarrand, J. P., Han, X.-Y., Rolston, K. V. I., Safdar, A., RAAD, I. I., et al. (2003) · Medicine · doi:10.1097/01.md.0000091182.93122.8e · Cited by 129
Variation in Susceptibility of Bloodstream Isolates ofCandida glabratato Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 128
Self-citation
Comparative Evaluation of Etest and Sensititre YeastOne Panels against the Clinical and Laboratory Standards Institute M27-A2 Reference Broth Microdilution Method for Testing Candida Susceptibility to Seven Antifungal Agents
Alexander, B. D., Byrne, T. C., Smith, K. L., Hanson, K. E., Anstrom, K. J., Perfect, J. R., & Reller, L. B. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01840-06 · Cited by 129
In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of RareCandidaSpecies as Determined by CLSI Broth Microdilution Methods
Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125
Self-citation
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review
Somayaji, R., Parkins, M. D., Shah, A., Martiniano, S. L., Tunney, M. M., Kahle, J. S., Waters, V. J., Elborn, J. S., Bell, S. C., Flume, P. A., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.01.008 · Cited by 121
Antifungal drug resistance mechanisms
Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121
Antifungal Susceptibility for Common Pathogens of Fungal Keratitis in Shandong Province, China
Xie, L., Zhai, H., Zhao, J., Sun, S., Shi, W., & Dong, X. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.04.019 · Cited by 115
Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Evaluation of Amphotericin B Interpretive Breakpoints for Candida Bloodstream Isolates by Correlation with Therapeutic Outcome
Park, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113
Trends in antifungal susceptibility testing using CLSI reference and commercial methods
Cantón, E., Espinel‐Ingroff, A., & Pemán, J. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.7.1.107 · Cited by 113
Echinocandins: the expanding antifungal armamentarium
Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00136-13 · Cited by 105
Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis
Dannaoui, É., Abdul, M., Arpin, M., Michel-Nguyen, A., Piens, M. A., Favel, A., Lortholary, O., Dromer, F., & the French Cryptococcosis Study Group (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-05 · Cited by 102
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
Candida rugosa , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
Pfaller, M. A., Diekema, D. J., Colombo, A. L., Kibbler, C. C., Ng, K. P., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00863-06 · Cited by 99
Self-citation
Spectrum of fungal keratitis in central China
Wang, L., Sun, S., Jing, Y., Han, L., Zhang, H., & Yue, J. (2009) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2009.02155.x · Cited by 98
ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia
Arendrup, M. C., Billé, J., Dannaoui, É., Ruhnke, M., Heussel, C. P., & Kibbler, C. C. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.246 · Cited by 88
Pharmacokinetics/pharmacodynamics of echinocandins
Theuretzbacher, U. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1228-z · Cited by 86
Relationship of In Vitro Susceptibility to Moxifloxacin and In Vivo Clinical Outcome in Bacterial Keratitis
Lalitha, P., Srinivasan, M., Manikandan, P., Bharathi, M. J., Rajaraman, R., Ravindran, M., Cevallos, V., Oldenburg, C. E., Ray, K. J., Toutain-Kidd, C. M., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis189 · Cited by 81
Antifungal Susceptibility Testing of Fusarium: A Practical Approach
Al‐Hatmi, A. M. S., Curfs-Breuker, I., de Hoog, S., Meis, J. F. G. M., & Verweij, P. E. (2017) · Journal of Fungi · doi:10.3390/jof3020019 · Cited by 84
Antifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01551-06 · Cited by 77
Self-citation
Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
Barreto, E. F., Webb, A. J., Pais, G. M., Rule, A. D., Jannetto, P. J., & Scheetz, M. H. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000446 · Cited by 80
Antimicrobial Susceptibility Testing: A Primer for Clinicians
Kuper, K. M., Boles, D. M., Mohr, J., & Wanger, A. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.11.1326 · Cited by 77
Antifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 81
Clinical perspectives on echinocandin resistance among Candida species
Shields, R. K., Nguyen, M. H., & Clancy, C. J. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000215 · Cited by 78
Caspofungin
Keating, G. M., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363200-00008 · Cited by 75
Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy
Groll, A. H., & Kolve, H. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1108-6 · Cited by 72
Malassezia: Zoonotic Implications, Parallels and Differences in Colonization and Disease in Humans and Animals
Hobi, S., Cafarchia, C., Romano, V., & Barrs, V. R. (2022) · Journal of Fungi · doi:10.3390/jof8070708 · Cited by 78
Antifungal resistance in dermatology
Pai, V. V., Ganavalli, A., & Kikkeri, N. (2018) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_131_17 · Cited by 69
Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., & Jones, R. N. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.07.007 · Cited by 71
Self-citation
Association between In Vitro Susceptibility to Natamycin and Voriconazole and Clinical Outcomes in Fungal Keratitis
Sun, C. Q., Lalitha, P., Prajna, N. V., Karpagam, R., Geetha, M., O’Brien, K. S., Oldenburg, C. E., Ray, K. J., McLeod, S. D., Acharya, N. R., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.03.004 · Cited by 68
MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method
Borman, A. M., Fraser, M., Palmer, M., Székely, A., Houldsworth, M., Patterson, Z., & Johnson, E. M. (2017) · Journal of Fungi · doi:10.3390/jof3020027 · Cited by 68
Interaction between Antibiotic Resistance, Resistance Genes, and Treatment Response for Urinary Tract Infections in Primary Care
Ho, H. J. A., Tan, M. X., Chen, M. I.-C., Tan, T. Y., Koo, S. H., Koong, A. Y. L., Ng, L. P., Hu, P. L., Tan, K. T., Moey, P. K. S., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00143-19 · Cited by 67
Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3137-3141.2004 · Cited by 66
Self-citation
Is antifungal resistance a cause for treatment failure in dermatophytosis: A study focused on tinea corporis and cruris from a tertiary centre?
Arora, P., Sardana, K., Kaur, R., Goyal, R., & Ghunawat, S. (2018) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_137_17 · Cited by 66
Antifungal Resistance Regarding Malassezia pachydermatis: Where Are We Now?
Peano, A., Johnson, E. M., Chiavassa, E., Tizzani, P., Guillot, J., & Pasquetti, M. (2020) · Journal of Fungi · doi:10.3390/jof6020093 · Cited by 65
Infections in Hospitalized Cancer Patients
Delgado, A. M., & Guddati, A. K. (2021) · World Journal of Oncology · doi:10.14740/wjon1410 · Cited by 71
Medically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 64
diskImageR: quantification of resistance and tolerance to antimicrobial drugs using disk diffusion assays
Gerstein, A. C., Rosenberg, A., Hecht, I., & Berman, J. (2016) · Microbiology · doi:10.1099/mic.0.000295 · Cited by 63
Activity of antibiotics against Fusarium and Aspergillus
Day, S., Lalitha, P., Haug, S., Fothergill, A. W., Cevallos, V., Vijayakumar, R., Prajna, N. V., Acharya, N. R., McLeod, S. D., & Lietman, T. M. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.142364 · Cited by 63
Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus
Torres, H. A., Rivero, G., Lewis, R. E., Hachem, R. Y., RAAD, I. I., & Kontoyiannis, D. P. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00013-0 · Cited by 63
Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure
Diekema, D. J., & Pfaller, M. A. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502451 · Cited by 62
Self-citation
Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods: Report From the College of American Pathologists Microbiology Surveys Program (2001–2003)
Pfaller, M. A., & Jones, R. N. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-767-paoaaa · Cited by 62
Self-citation
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61
Self-citation
In vitro susceptibility testing in fungi: a global perspective on a variety of methods
Lass‐Flörl, C., Perkhofer, S., & Mayr, A. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01813.x · Cited by 58
Natamycin in the treatment of keratomycosis: Correlation of treatment outcome and in vitro susceptibility of fungal isolates
Sharma, S., Pradhan, L., Nalamada, S., Sahu, S., Das, S., & Garg, P. (2011) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.86328 · Cited by 58
Susceptibility Test Methods: General Considerations
Turnidge, J. D. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch70 · Cited by 57
The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agentsin vitro
Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.2 · Cited by 56
Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01451-13 · Cited by 56
Azole‐resistant Candida spp. – emerging pathogens?
Tobudic, S., Kratzer, C., & Presterl, E. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02146.x · Cited by 57

Authors: Rex, J. H., & Pfaller, M. A.
Affiliations: Texas Medical Center (US)
University of Iowa (US)
Corresponding author: Rex, John H.
ORCID: Rex, John H.
Pfaller, Michael A.
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2002-10-15
Volume: 35
Issue: 8
Pages: 982-989
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1086/342384
OpenAlex: W2118836068
Cited by: 361
References: 64
Citations by year: 2026: 5 · 2025: 5 · 2024: 10 · 2023: 11 · 2022: 13 · 2021: 8 · 2020: 17 · 2019: 10 · 2018: 16 · 2017: 21 · 2016: 13 · 2015: 14 · 2014: 24 · 2013: 17 · 2012: 14
FWCI: 10.38
Type: journal article
Language: en
Open access: closed
Locations: Clinical Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords: antifungal susceptibility testing, in vitro susceptibility, predictive utility, antifungal resistance, Candida species, azole antifungals, fungal infection, treatment response
MeSH terms: Amphotericin B, Antifungal Agents, Azoles, Candida, Clinical Trials as Topic, Flucytosine, Humans, Microbial Sensitivity Tests, Statistics as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Has antifungal susceptibility testing come of age

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks